Event
US FDA approves first generic version of lenacapavir HIV prevention injection
The US FDA has approved the first generic version of the twice-yearly HIV prevention injection lenacapavir.
The United States Food and Drug Administration has approved the first generic version of lenacapavir. This injection for HIV prevention is administered twice a year and is projected to cost approximately US$40 annually in 120 low- and middle-income countries.
The FDA is a federal agency within the United States Department of Health and Human Services that supervises pharmaceutical drugs, vaccines, and other medical products.
Headlines and summaries are written by AI for Outer News (RS Elite Pro s.r.o.) from Wikipedia's text and are not reviewed by a person. They can contain mistakes: before you rely on one, read the original.
Read on WikipediaSource: Wikipedia: Current events · CC BY-SA 4.0